Influence of the progression of pleural neoplasia on the outcome of pleurodesis in mice.
lung neoplasia
metastasis
pleural effusion
pleurodesis
talc
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
26 May 2020
26 May 2020
Historique:
received:
18
07
2019
accepted:
19
03
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
12
6
2020
Statut:
epublish
Résumé
Experimental study aimed at evaluating whether pleural neoplastic disease is associated with the degree of pleural fibrosis over time caused by talc pleurodesis. The study describes changes in levels of inflammatory mediators and determines whether the course of time involved in progression of neoplastic pleural disease is the factor that influences safety of talc pleurodesis usage in mice. Animals were randomized into two groups: Cancer group (CG) that received intrapleural injection of Lewis cells or Saline group (SG) that received saline injection. After, the animals were subdivided into Early (pleurodesis 3 days after pleural injection) and Late (pleurodesis 7 days after pleural injection) groups. Half of the animals in each group were euthanized 24 hours after pleurodesis (to obtain the inflammatory data); the remaining animals were killed after 8 days (to obtain the scores of pleural fibrosis). CGs had lower fibrosis scores than SGs comparing early phases to late phases. Inflammation scores were lower in CGs, particularly in Late group. In SGs the inflammation was intense in 100% of the animals. In Late CG group pleural adhesions had the lowest scores; we found intense fibrosis only in SGs. VEGF and LDH levels had increased in animals with cancer, particularly in Late group. Systemic distribution of talc occurred only in Late CG. The time for pleural neoplasia to evolve is inversely proportional to the degree of pleural fibrosis. Earlier pleurodesis yielded the best results related to fibrosis, with less systemic inflammation and is safer in mice.
Identifiants
pubmed: 32523654
doi: 10.18632/oncotarget.27610
pii: 27610
pmc: PMC7260117
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2002-2009Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Clinics (Sao Paulo). 2007 Oct;62(5):627-34
pubmed: 17952325
Respir Med. 2009 Apr;103(4):595-600
pubmed: 19046861
Chest. 2016 Sep;150(3):673-9
pubmed: 27217265
J Transl Med. 2015 Sep 15;13:302
pubmed: 26373420
Rev Mal Respir. 2003 Dec;20(6 Pt 1):881-8
pubmed: 14743089
Eur Respir J. 2006 Nov;28(5):929-32
pubmed: 16870666
Eur Respir J. 2010 Feb;35(2):450-2
pubmed: 20123852
J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79
pubmed: 7673356
Ann Surg Oncol. 1999 Jun;6(4):373-8
pubmed: 10379858
Oncotarget. 2017 Sep 28;8(62):105093-105102
pubmed: 29285236
Respir Med. 2009 Jan;103(1):91-7
pubmed: 18789662
J Clin Oncol. 1989 Oct;7(10):1518-27
pubmed: 2674337
Respiration. 1998;65(2):108-13
pubmed: 9580921
Clinics (Sao Paulo). 2013 Apr;68(4):557-62
pubmed: 23778345
Growth Factors. 2012 Oct;30(5):304-9
pubmed: 23017018
Chest. 2009 Aug;136(2):361-368
pubmed: 19349389
Respiration. 2008;75(2):121-33
pubmed: 18332619
Respiration. 2012;83(2):91-8
pubmed: 22286268
Ann Intern Med. 1988 Mar;108(3):345-9
pubmed: 3341671
Chest. 1999 Jan;115(1):190-3
pubmed: 9925083
Chest. 2005 Sep;128(3):1798-804
pubmed: 16162789
Clin Cancer Res. 1999 Nov;5(11):3364-8
pubmed: 10589746
Lung. 2011 Apr;189(2):151-5
pubmed: 21331598